Home » Pipeline
Pipeline
March 15, 2020
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| Debiopharm | Debio 0123 | refractory solid tumors that have recurred or progressed following prior platinum-based chemotherapy and for which no standard treatment is available | initiation of phase 1 trial |
| FSD Pharma | Ultra Micro-Plmitolylethanolamide (PEA) | inflammatory conditions | initiation of phase 1 trial |
| Virometix | V-306 vaccine | respiratory syncytial virus | initiation of phase 1 trial |
| Actinium Pharma | Actimab-A CLAG-M combination | relapsed or refractory acute myeloid leukemia | first patient treated in third and final cohort of phase 1 trial |
| Innate Pharma AstraZeneca |
IPH5201 alone and in combination with durvalumab with or without oleclumab | advanced solid tumors | first patient dosed in phase 1 trial |
| Medivir AB | MIV-818 | advanced liver cancer | first patient dosed in phase 1b study |
| InMed Pharma | INM-755 | epidermolysis bullosa and potentially other dermatological diseases | patient enrollment complete in phase 1 study |
| Albireo | elobixibat | nonalcoholic steatohepatitis and nonalcoholic fatty liver disease | patient enrollment complete in phase 2 study |
| Tenax Therapeutics | levosimendan | pulmonary hypertension and heart failure with preserved ejection fraction | patient enrollment complete in phase 2 study |
| Palvella Therapeutics | PTX-022 (QTORIN 3.9% rapamycin anhydrous gel) | Pachyonychia Congenita | patient enrollment complete in phase 2/3 study |
| QED Therapeutics | infigratinib | adjuvant treatment of invasive urothelial carcinoma | first patient dosed in phase 3 trial |
| ARVOBIO | AVR-RD-04 gene therapy | cystinosis | Orphan Drug designation granted by FDA |
| TG Therapeutics | umbralisib | follicular lymphoma | Orphan Drug designation granted by FDA |
| Spero Therapeutics | oral SPR720 | nontuberculous mycobacterial infection | Orphan Drug designation granted by FDA |
| Janssen | JNJ-6372 | metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations where the disease has progressed while the patient is on or after receiving platinum-based chemotherapy | Breakthrough Therapy designation granted by FDA |
| Neuronetics | NeuroStar Advanced Therapy System | bipolar depression | Breakthrough Device designation granted by FDA |
| Aerin Medical | RhinAer Stylus | chronic rhinitis | approved by the FDA |
| Allergan | Durysta (bimatoprost implant) | open-angle glaucoma or ocular hypertension | approved by the FDA |
| AltaThera Pharmaceuticals | Sotalol IV | atrial fibrillation | new indications approved by the FDA |
| Boehringer-Ingelheim | Ofev (nintedanib) | chronic fibrosing interstitial lung diseases with a progressive phenotype | approved by the FDA |
| Bristol-Myers Squibb | Opdivo (nivolumab) and Yervoy (ipilimumab) | hepatocellular carcinoma which has been previously treated with Bayer’s Nexavar (sorafenib) | approved by the FDA |
| Recordati | Isturisa (osilodrostat) | Cushing's disease when pituitary surgery is not an option or has not been curative | approved by the FDA |
